An update from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. announced the issuance of 112,986 shares of common stock as part of its block admission facility, following the exercise of share options and vesting of restricted stock units. This brings the total issued stock capital to 105,958,833 shares, which shareholders can use to calculate their stock interests. This move reflects MaxCyte’s ongoing efforts to support its growth and maintain its position in the cell-based therapeutics market.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering industry, specializing in platform technologies that advance the discovery, development, and commercialization of next-generation cell-based therapeutics. Their ExPERT™ platform, which utilizes Flow Electroporation® technology, supports the growing cell therapy market and includes instruments, processing assemblies, and software protocols. MaxCyte aims to transform human health by providing partners with comprehensive technology and support.
YTD Price Performance: -18.52%
Average Trading Volume: 40,537
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £279.4M
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.